CA2874819A1 — Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Assigned to Daiichi Sankyo Co Ltd · Expires 2013-12-12 · 12y expired
What this patent protects
The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which, in certain embodiments, is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The disc…
USPTO Abstract
The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which, in certain embodiments, is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The disclosure provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.